MHRA kicks off new accelerated drug approval pathway with ‘innovation passports’

As the UK no longer participates in the European Medicines Agency, the country’s drug regulator is getting creative in trying to attract top biopharma companies to submit applications to the EU and UK separately.

As part of this creative push, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s standalone medicines and medical devices regulator, last week unveiled a new accelerated drug approval pathway, known as the Innovative Licensing and Access Pathway (ILAP).